Sarcoidosis may involve muscles, bones or joints, causing pain, stiffness, weakness or reduced mobility. Similar symptoms can have other causes, so assessment may include examination, blood tests and imaging. Treatment depends on the confirmed problem and may involve medicines, rehabilitation or pain management. Report new weakness, marked swelling or rapidly worsening symptoms to your healthcare team.
Review of the musculoskeletal manifestations of sarcoidosis
Katie Bechman, Dimitrios Christidis, Sarah Walsh, Surinder S Birring, James Galloway — review for rheumatologists, originally published online in 2017 and in Rheumatology 57(5), 2018.
Rheumatology key messages
Musculoskeletal manifestations occur in approximately one-third of patients with sarcoidosis.
Tenosynovitis and periarthritis are more common in patients with sarcoidosis than true joint synovitis.
Methotrexate is the most commonly used steroid-sparing drug in the treatment of patients with sarcoidosis.
Introduction
The purpose of this review is to summarise sarcoidosis in a way relevant to rheumatologists. Sarcoidosis is a systemic inflammatory disease characterised by non-caseating granulomas (Figure 1). It is known for its many manifestations, which often cross medical specialty boundaries. The earliest descriptions came from Hutchinson, a nineteenth-century London clinician whose appropriately broad practice included internal medicine, dermatology, venereology, ophthalmology and surgery. In 1858, Hutchinson encountered a 58-year-old coal-wharf worker with purple, symmetrical skin plaques on his legs and arms that had gradually developed over the preceding two years [1]. To the authors’ knowledge, this was the index case of sarcoidosis in the medical literature.
Granuloma formation is the end result of a coordinated Th1 cytokine response that stimulates macrophages to differentiate into epithelioid cells and fuse into giant cells [2]. As the granuloma develops, its central regions become densely packed with macrophages, epithelioid cells and multinucleated giant cells, surrounded by a peripheral rim of CD8 T cells, mast cells and fibroblasts. Most cases resolve spontaneously, but obliterative fibrosis develops in 20–25% of patients [3].
The epidemiology remains poorly defined. Cases have been reported worldwide across all ethnic groups and sexes, although incidence peaks in young adults and the disease is more common in Black people [4].
Musculoskeletal manifestations are seen in one-quarter to one-third of patients, with possible involvement of joints, bones and muscles. Severity also varies widely, from arthralgia to extensive destructive bone lesions.
A rheumatologist may encounter sarcoidosis when it presents primarily with musculoskeletal symptoms, when a patient with established sarcoidosis develops new musculoskeletal symptoms, or when advice on immunosuppression is sought. This article reviews musculoskeletal manifestations and addresses these situations.
Rheumatic manifestations of sarcoidosis
Acute arthritis (Löfgren syndrome)
The most common musculoskeletal manifestation is acute arthritis as part of Löfgren syndrome: a triad of symmetrical hilar adenopathy, joint pain and erythema nodosum [10]. The syndrome is seasonal, with clusters in spring [11]. It is associated with specific genetic factors that may distinguish it from other manifestations of sarcoidosis. There is a strong association with HLA-DRB1 alleles, and HLA-DRB1*03-positive patients with Löfgren syndrome have an excellent prognosis [12].
The ankles are the most commonly affected joints, with bilateral involvement in most patients [13]. Other sites may include the knees, wrists, elbows and metacarpophalangeal (MCP) joints. On ultrasound, swelling is usually attributable to periarticular soft-tissue swelling and tenosynovitis. True joint synovitis or effusions are uncommon and, when present, are usually minor and show no power Doppler activity [14]. Synovial fluid analysis is not required for diagnosis, but when performed it reveals a mild inflammatory infiltrate dominated by mononuclear cells. Histopathological examination of the synovium typically shows no granulomatous reaction [15].
Chest radiography reveals bilateral hilar adenopathy in 90% of patients; this is asymptomatic [13]. Erythema nodosum is not universal, occurring in approximately 40%, and is reported more often in White people and women [16]. Fever and other constitutional symptoms may be present.
The natural course of Löfgren syndrome is complete resolution over several months. A minority take longer to recover fully (18–24 months) [16]. Only a very small proportion experience recurrence after resolution. Joint destruction is extremely rare [17].
The review describes Löfgren syndrome as so characteristic that history, examination and chest radiography are usually sufficient for diagnosis, and calls it the only situation in which histological confirmation need not be sought.
When considering Löfgren syndrome, clinicians should recognise other causes of erythema nodosum associated with polyarthritis and hilar adenopathy, including bacterial, fungal and viral infections. Hilar adenopathy is usually asymptomatic, so respiratory symptoms should raise suspicion. In high-risk patients or regions where tuberculosis, histoplasmosis or coccidioidomycosis occur, biopsy with appropriate stains and cultures should be performed.
Chronic arthritis
Chronic arthritis associated with sarcoidosis usually occurs alongside other extrapulmonary manifestations, particularly skin involvement [18–20]. The typical pattern is symmetrical oligoarthritis of medium to large joints [13, 21]. True synovitis must be distinguished from tenosynovitis, which is more common. Symmetrical inflammatory lesions in the wrist extensor tendon compartment should raise suspicion of musculoskeletal sarcoidosis. Destructive arthritis is described less often [22]. True synovitis in large joints requires further assessment. Synovial fluid analysis is not diagnostic, although it tends to show a milder inflammatory infiltrate than other arthritides, with lymphocyte predominance [23]. Synovial tissue should be sampled to demonstrate a granulomatous infiltrate and exclude alternatives such as infection, especially tuberculosis.
Sarcoid monoarthritis is rare in cohort studies despite numerous case reports, possibly reflecting reporting bias. Gout, calcium pyrophosphate deposition and septic arthritis must be excluded. The relationship between gout and sarcoidosis has been recognised for decades and is thought to result from altered urate metabolism leading to hyperuricaemia [24]. Gouty arthritis in sarcoidosis should be confirmed by joint aspiration and documentation of monosodium urate crystals.
Jaccoud arthropathy
Jaccoud arthropathy is characterised by deforming but non-erosive arthritis. It was classically described in connective tissue diseases, particularly systemic lupus erythematosus (SLE). Jaccoud arthritis in sarcoidosis has been described in case reports [25], usually in the setting of extensive internal-organ involvement later in the disease course. Biopsy reveals tendon fibrosis with epithelioid-cell granulomas in muscles and tendon sheets.
Axial disease
Spinal involvement in sarcoidosis is often asymptomatic, and its true prevalence is unknown. Vertebral lesions may be the first manifestation or an incidental finding during radioisotope imaging for other reasons, such as assessing pulmonary disease activity [26]. Spinal lesions may be lytic, sclerotic or both and may affect any spinal segment [27]. Sacroiliitis has been described in several case reports [28]. While spondyloarthritis (SpA) prevalence in the general population ranges from 1 to 1.9%, Erb and colleagues [29] reported a prevalence of 6% in patients with sarcoidosis, suggesting a possible association. Involvement may be unilateral, and biopsy typically confirms granulomatous disease [30].
Dactylitis
Dactylitis is one of the best-known presentations of musculoskeletal involvement in sarcoidosis. Most clinicians recognise this pattern, which is almost exclusively associated with chronic systemic involvement. It has been described alongside lupus pernio and other forms of chronic cutaneous sarcoidosis. It typically develops symmetrically, most often affecting the second and third phalanges while sparing the MCP joints [31].
Dactylitis is associated with swelling and erythema and resembles psoriatic arthritis (PsA) [32]. It is more common in people of African ancestry. Histology confirms tenosynovitis and soft-tissue granulomas. Radiographs reveal cystic bone lesions with a characteristic lattice-like appearance [33]. Joint-line erosions are not characteristic, although cystic lesions can lead to joint collapse.
Myopathy
Three distinct clinical patterns of muscle involvement are recognised: chronic, nodular and acute myopathy. Patients with sarcoidosis report myalgia more often than healthy controls [34]. Skeletal-muscle involvement is estimated to occur in up to half of all patients [35], but is symptomatic in fewer than 3% [36]. Patients often report general weakness, fatigue and reduced exercise capacity. Distinguishing symptoms attributable to respiratory disease from those due to muscle disease is challenging [37]. Diagnosis can be difficult when myopathy develops during corticosteroid treatment, because corticosteroid myopathy has a distribution similar to sarcoid myopathy. Muscle biopsy is particularly useful in distinguishing these situations.
Chronic sarcoid myopathy
Chronic myopathy is the most common form, occurring mainly in women aged 50–60. It presents with an insidious onset of symmetrical proximal muscle weakness; trunk and neck muscles may also be involved [38]. Muscle enzyme levels are often normal, while neurophysiology shows myopathic changes comparable with other inflammatory muscle disorders [36]. When performed, muscle biopsy typically shows granulomatous changes and a cellular infiltrate of lymphocytes and macrophages, with endomysial and perivascular inflammation [39, 40]. Muscle tissue may be abnormal even without muscle symptoms and may provide a biopsy site when other affected organs are less accessible for tissue diagnosis. MRI may reveal muscle atrophy with fatty degeneration [41]. Some earlier MRI studies did not include fat suppression or short tau inversion recovery (STIR) sequences, which were subsequently shown to be more sensitive to abnormalities. The review describes FDG-PET/CT as having become the most sensitive imaging technique for muscle involvement in the preceding years [42].
Nodular sarcoid myopathy
Nodular sarcoid myopathy is characterised by single or multiple muscle nodules [43]. Limb involvement is usually symmetrical [40, 44]. Nodules are often painful and may eventually cause contractures. Serum muscle enzyme levels and neurophysiological studies are normal. Macroscopic histological analysis shows lesions between muscle bundles without direct involvement of muscle fibres [45]. MRI is useful for locating this pattern of myopathy [46]. Nodules appear round, ovoid or spindle-shaped and extend along muscle fibres [47]. The centre shows reduced signal intensity because of persistent inflammation within the granuloma, followed by replacement with fibrous tissue. The peripheral region shows slightly increased signal intensity on T1-weighted images because of its high cellular content, and markedly increased intensity on T2-weighted images because of peripheral oedema associated with granulomatous inflammation [47].
Acute sarcoid myopathy
Acute myopathy is the rarest form of sarcoid myopathy. It usually occurs early in the course of sarcoidosis and in patients younger than 40 [40]. The presentation resembles other inflammatory myopathies, with rapid onset of proximal weakness and myalgia associated with elevated creatine kinase levels. Muscle biopsy shows non-caseating granulomas with marked lymphocytic infiltration [48].
Bone involvement
Bone involvement is usually asymptomatic and often discovered on imaging performed for other reasons. It is estimated to occur in 1–15% of patients [49]. It is seen in all ethnic groups, although the preferred sites may vary, with bone cysts in the hands and feet more common in Black people [50]. Bone involvement is often accompanied by overlying skin disease. Soft-tissue swelling and skin involvement precede bone abnormalities and may be seen up to four years before visible radiological changes [51].
Three patterns of bone lesions are described: a permeative, “moth-eaten” appearance affecting the phalangeal cortex and accompanied by soft-tissue swelling; lytic lesions, also called bone cysts, appearing as cortical defects in the heads of the phalanges or round punched-out lesions; and sclerotic lesions in the spine resembling metastatic disease [50]. Sarcoid bone lesions are more often cystic than sclerotic or lytic.
Bone involvement most commonly affects the proximal and middle phalanges, but the skull, nasal bones, maxilla, sternum, ribs, vertebrae, pelvis, tibia and femur may also be involved. Peripheral bone involvement is more often described in the literature, but increasing use of advanced imaging (PET-CT or MRI) is revealing a greater proportion of axial involvement. Sparks and colleagues [52] identified incidentally detected sarcoidosis involving the spine or pelvis in 90% of their cohort, while only 10% had isolated appendicular skeletal involvement. Every patient in that study had more than one affected bone.
Serum calcium and alkaline phosphatase levels are usually normal despite multiple affected bones. This reflects a different pathophysiology from conditions such as Paget disease, malignancy, osteoporosis or osteomalacia [52].
Principles of treatment
Most patients have asymptomatic, non-progressive disease or experience spontaneous remission and therefore do not require treatment. Löfgren syndrome is self-limiting, and non-steroidal anti-inflammatory drugs (NSAIDs) are sufficient in many circumstances [53].
For more severe disease, treatment aims to reduce the burden of granulomatous inflammation and prevent organ damage. For joint manifestations, the review reports that prednisolone 10–20 mg is usually sufficient to control acute arthritis, with lower doses acceptable in chronic disease [20]. There are no randomised controlled trials of treatment for sarcoid myopathy, and corticosteroid regimens resemble those used for inflammatory myopathies. They are generally effective in acute and nodular muscle sarcoidosis but less effective in chronic sarcoid myopathy. Despite initial success, a high relapse rate has been reported [44]. Intralesional triamcinolone injections have been used successfully for painful nodular lesions [54].
Bone involvement often indicates chronic, severe sarcoidosis involving multiple organs. Bone lesions alone are not an indication for specific treatment unless symptomatic. Corticosteroids may relieve soft-tissue swelling but do not improve abnormal bone architecture [55]. Therapeutic vitamin D use requires caution because disrupted calcium metabolism due to extrarenal calcitriol synthesis is well recognised in sarcoidosis.
Steroid-sparing agents are commonly added for corticosteroid-resistant disease or when high steroid doses are needed for a prolonged period. Controlled-trial data to guide treatment are limited, and treatment must be tailored to the affected organ or organs. The choice of steroid-sparing agent is largely unsupported by an evidence base, so no clear recommendation can be made.
The largest body of evidence concerns methotrexate (MTX), which has a substantial steroid-sparing effect in sarcoid interstitial lung disease [56, 57]. In this steroid-sparing context, the review states that the World Association of Sarcoidosis and Other Granulomatous Disorders recommends MTX as first-line treatment [58]. There are no trials of MTX in musculoskeletal sarcoidosis; although positive case reports exist, publication bias is likely [56, 59, 60]. The authors’ experience of MTX for musculoskeletal manifestations is mixed, with clearer responses in objective synovitis and less obvious benefit in tenosynovitis alone. MTX has also been used in steroid-resistant acute sarcoid myositis and bone disease, with variable success [60]. Fujita and colleagues [48] reviewed 18 patients with sarcoid myositis, most of whom responded successfully to corticosteroids. Of five patients resistant to corticosteroids, three received additional low-dose MTX and responded dramatically, without prominent adverse effects.
To facilitate steroid-dose reduction in extrapulmonary sarcoidosis [61], leflunomide (LEF) may be used as an alternative or addition to MTX, although little information is available about its use in musculoskeletal disease. Hydroxychloroquine (HCQ) has been used successfully for acute arthritis and skin involvement [62, 63]. Mycophenolate mofetil (MMF) has shown effectiveness in neurosarcoidosis [64], although MTX significantly prolongs relapse-free survival and is preferred over MMF [65]. In renal disease, benefits from azathioprine (AZA) and MMF have been reported only in small case series. These agents are used instead of MTX, which is not recommended in that setting because clearance is almost exclusively renal [66].
TNF-α has a key role in granuloma formation and is therefore a potential therapeutic target. Several case reports document success in cutaneous, cardiac, neurological and musculoskeletal disease [64, 67–69]. Although adalimumab was found effective for skin involvement [70], larger randomised controlled trials in pulmonary disease produced disappointing results [71, 72]. The review states that, at that time, there were no trial data supporting anti-TNF use in sarcoidosis. Positive individual case reports describe rituximab in cardiac and neurological sarcoidosis [73–75].
Conclusion
Sarcoidosis remains difficult to diagnose, with many manifestations in the musculoskeletal system. Histological evidence of granulomatous inflammation is central to diagnosis. Clinicians must be aware of other granulomatous diseases that can mimic sarcoidosis. Keeping an open mind about the diagnosis is essential, particularly in patients whose diagnosis has been most difficult.
Treatment recommendations for musculoskeletal manifestations are largely based on expert opinion and extrapolation from the pulmonary evidence base. The review reports no globally available guidelines for musculoskeletal sarcoidosis. Randomised controlled trials are warranted, but the rarity of the disease makes them difficult to conduct. Validated outcome measures for musculoskeletal sarcoidosis are also lacking.
Rheumatologists have an important role, ensuring an accurate syndromic diagnosis of musculoskeletal manifestations and contributing expertise in managing long-term immunosuppression.
Source with references:
https://academic.oup.com/rheumatology/article/57/5/777/4096668